Prime Medicine's application will test an FDA that has promised to speed new gene-editing treatments but has recently spurned ...

The firm believes that clinical data generated to date from two patients may be sufficient to support accelerated approval of PM359.

CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, ...

Discover how prime editing is redefining the future of medicine by offering highly precise, safe, and versatile DNA corrections, bringing hope for more effective treatments for genetic diseases while ...

Clustered, regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (CRISPR-Cas9) are genome editing tools. 1 After their potential in therapeutics was recognized, ...

While researchers have long appreciated the enormous potential of genome editing to treat disease, applications of these technologies in humans have historically been limited by safety concerns. Even ...

In a study published in Nature Biotechnology, GAO Caixia's group from the Institute of Genetics and Developmental Biology of the Chinese Academy of Sciences has developed a series of new prime editors ...

Despite the copious demands of his administrative positions as the White House chief science advisor (and until last year, the director of the NIH), Francis Collins, MD, PhD, has continued to run a ...

On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both ...